Hibiocy

Hibiocy Co., Ltd. is a Thailand-based biotechnology company focused on the development and commercialization of innovative respiratory-care medical devices and antibody-based therapies. Established in 2021, the company operates as a wholly-owned subsidiary of the publicly traded Rojukiss International Public Company Limited (KISS). Hibiocy's flagship product, Vaill CoviTRAP, is the world's first human antibody-based nasal spray approved for the prevention of COVID-19, developed through a landmark collaboration with Chulalongkorn University and the Government Pharmaceutical Organization (GPO). The company utilizes advanced antibody technology to create protective barriers in the nasal cavity that inhibit viral attachment and infection. To support global distribution and manufacturing, Hibiocy maintains a strategic partnership with the CDMO GenScript ProBio. The company continues to research and develop new products to address a wider range of respiratory pathogens and healthcare needs.